Sam J Lubner

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. pmc Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study
    Sam J Lubner
    University of Wisconsin, Madison, WI 53792, USA
    J Clin Oncol 28:3491-7. 2010
  2. pmc A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer
    Sam J Lubner
    University of Wisconsin Carbone Cancer Center, Madison, USA
    Clin Colorectal Cancer 9:157-61. 2010
  3. pmc A preclinical and clinical study of lithium in low-grade neuroendocrine tumors
    Sam J Lubner
    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA
    Oncologist 16:452-7. 2011
  4. pmc A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study
    Noelle K Loconte
    University of Wisconsin Carbone Cancer Center and the University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, K6 548 CSC, Madison, WI 53792, USA
    Invest New Drugs 31:943-8. 2013
  5. pmc A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma
    Tabraiz A Mohammed
    D O, M S, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, Wisconsin 53792, USA
    Oncologist 16:835-43. 2011
  6. pmc A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors
    Noelle K Loconte
    University of Wisconsin Carbone Cancer Center, 600 Highland Ave, CSC K4 548, Madison, WI, 53792, USA
    Invest New Drugs 33:169-76. 2015
  7. pmc Phospholipid ether analogs for the detection of colorectal tumors
    Dustin A Deming
    Division of Hematology and Oncology, Department of Medicine, University of Wisconsin Madison, Madison, Wisconsin, United States of America
    PLoS ONE 9:e109668. 2014

Collaborators

Detail Information

Publications7

  1. pmc Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study
    Sam J Lubner
    University of Wisconsin, Madison, WI 53792, USA
    J Clin Oncol 28:3491-7. 2010
    ..Secondary end points included overall survival (OS), time to progression (TTP), VEGF levels, and molecular studies of EGFR and k-ras...
  2. pmc A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer
    Sam J Lubner
    University of Wisconsin Carbone Cancer Center, Madison, USA
    Clin Colorectal Cancer 9:157-61. 2010
    ..This phase II study explores the efficacy and safety of a 2-day course of oxaliplatin/capecitabine (2DOC), with oxaliplatin given on day 1 and capecitabine given orally every 8 hours in high doses over 6 doses, mimicking FOLFOX6...
  3. pmc A preclinical and clinical study of lithium in low-grade neuroendocrine tumors
    Sam J Lubner
    University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA
    Oncologist 16:452-7. 2011
    ..Use of lithium chloride in murine models suppressed carcinoid cell growth, reduced GSK-3β levels, and reduced expression of chromogranin A. This study assessed the efficacy of lithium chloride in patients with NETs...
  4. pmc A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study
    Noelle K Loconte
    University of Wisconsin Carbone Cancer Center and the University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, K6 548 CSC, Madison, WI 53792, USA
    Invest New Drugs 31:943-8. 2013
    ..The recommended phase II dose of sorafenib in combination with 2DOC is 200 mg BID. There were infrequent grade 3 toxicities, most evident with sorafenib at 400 mg BID...
  5. pmc A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma
    Tabraiz A Mohammed
    D O, M S, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, Wisconsin 53792, USA
    Oncologist 16:835-43. 2011
    ..Thus, this study aimed to evaluate the role of VPA in treating NETs and to determine whether VPA induced the Notch signaling pathway signaling in vivo...
  6. pmc A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors
    Noelle K Loconte
    University of Wisconsin Carbone Cancer Center, 600 Highland Ave, CSC K4 548, Madison, WI, 53792, USA
    Invest New Drugs 33:169-76. 2015
    ..This phase I study was conducted to determine maximum tolerated dose (MTD), toxicities and efficacy of RO4929097 and capecitabine in advanced solid tumors...
  7. pmc Phospholipid ether analogs for the detection of colorectal tumors
    Dustin A Deming
    Division of Hematology and Oncology, Department of Medicine, University of Wisconsin Madison, Madison, Wisconsin, United States of America
    PLoS ONE 9:e109668. 2014
    ..Together, these compounds might enhance our ability to properly resect CRCs through better localization of the primary tumor and improved lymph node identification as well as detect distant disease...